Pellegrini Niamh Louise 4
4 · NEVRO CORP · Filed Feb 12, 2021
Insider Transaction Report
Form 4
NEVRO CORPNVRO
Pellegrini Niamh Louise
Chief Commercial Officer
Transactions
- Sale
Common Stock
2021-02-10$182.55/sh−750$136,913→ 30,328 total - Exercise/Conversion
Common Stock
2021-02-10$64.95/sh+750$48,713→ 31,078 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-10−750→ 66,325 totalExercise: $64.95Exp: 2029-07-14→ Common Stock (750 underlying)
Footnotes (3)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F2]Includes 30,328 restricted stock units.
- [F3]25% of the shares subject to the option vest on the first anniversary measured from July 15, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.